A Randomized, Single-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN RSV Vaccine in Healthy Adult Subjects

Trial Profile

A Randomized, Single-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN RSV Vaccine in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs MVA-BN RSV (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 23 Feb 2017 Six month follow-up data published in a Bavarian Nordic media release.
    • 29 Sep 2016 Results published in Bavarian Nordic media release.
    • 29 Sep 2016 According to Bavarian Nordic media release, data from this trial presented at the 10th International Respiratory Syncytial Virus Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top